The BCMA bonanza

A long and growing list of anti-BCMA candidates — including chimeric antigen receptor-T cell therapies, antibody–drug conjugates and bispecific antibodies — are contending to transform multiple myeloma treatment.

Search for this author in:

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Nature Reviews Drug Discovery 18, 481-484 (2019)

doi: 10.1038/d41573-019-00105-9

Updates & Corrections

  • Correction 17 June 2019: The development status of LCAR-B38M in Table 1 has been modified to phase II alone globally and the alternative code name JNJ-4528 has been added.

Nature Briefing

An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.